ArticleJournal of Korean medical science2020
Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in
Article in Journal of Korean medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Association Between Low-Dose Ethambutol Therapy and Optic Neuropathy inOpen forum infectious diseases · 2026Trial
- Article
- Sarcopenia: an overlooked predictor of the progression risk in pulmonary nontuberculous mycobacterial infections?Journal of thoracic disease · 2026Article
- Early treatment interruption and nutritional status as predictors of mortality in Mycobacterium avium complex pulmonary disease.PloS one · 2026Article
- Clinical efficacy of sitafloxacin-containing regimens for Mycobacterium avium complex pulmonary disease.BMC pulmonary medicine · 2025Article
- Clinical outcomes and adverse events of nontuberculous mycobacterial lung disease treated at an Italian tertiary referral center.Scientific reports · 2025Observational
- Management challenges and outcomes for non-tuberculous mycobacterial pulmonary disease.IJTLD open · 2024Article
- Epidemiological Characteristics of Nontuberculous Mycobacterial Pulmonary Disease in South Korea: A Meta-analysis of Individual Participant Data.Tuberculosis and respiratory diseases · 2024Article
- Risk factors for microbiological persistence after 6 months of treatment forMicrobiology spectrum · 2023Article
- Treatment outcomes and relapse in patients withMicrobiology spectrum · 2023Article
- Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.Microbiology spectrum · 2023Article
- Radiologic Subtypes and Treatment Outcome of Unclassifiable TypeJournal of Korean medical science · 2023Article
- Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.Antimicrobial agents and chemotherapy · 2022Article
- Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system.BMC infectious diseases · 2022Article
- Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.Antimicrobial agents and chemotherapy · 2022Article
- Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLong-term administration of ethambutol (EMB) for
methodsAmong patients diagnosed with MAC-LD between January 2001 and December 2014, 508 patients whose treatment was initiated with standard regimen until May 2018 were enrolled at a tertiary referral center in Korea. Of these 508 patients, 60 (11.8%) discontinued EMB due to various adverse effects. Among these 60 patients, treatment outcomes were analyzed for 44 patients by comparing their outcomes with those of matched subjects who received the standard treatment regimen without EMB discontinuation.
resultsThe mean age of the 60 patients who discontinued EMB was 64.4 years. Ocular toxicity was the most common cause of discontinuation of EMB (75.0%, 45/60). The mean duration of EMB administration before its discontinuation was 7.0 ± 4.6 months. The treatment failure rate of the 44 patients with EMB discontinuation analyzed for treatment outcome was 29.6%, which was higher than that of the matched patients who received the standard regimen (18.3%), although the difference was not significant (
conclusionThese findings suggest that treatment outcomes are unsatisfactory in patients with MAC-LD who discontinue EMB owing to adverse events. Notably, there was a statistically significant high failure rate in patients who were prescribed fluoroquinolone to replace EMB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.